Shanghai – April 28, 2014 – Shanghai MicroPort Medical (Group) Co ("MicroPort") released 35 new products, mostly designed and manufactured by MicroPort and its subsidiaries, to its nationwide distributors. These new products, cover a wide range of business segments including cardiovascular, orthopedic, electrophysiological, endovascular, neurovascular, surgical, cardiac rhythm management devices, and have attracted more than 260 participants nationwide, seeking opportunities to act as product distributors.
The event features several star products that are about to shake current markets and lead future development in their respective segments. One is Firehawk Rapamycin Target Eluting Coronary Stent, the world’s first and only Target Eluting Stent ("TES") that enables the devise to achieve the same clinic efficacy as the traditional drug-eluting stent ("DES") with the least drug dosage. Compared to DES, its unique design lowers around 68 percent of drug use, greatly improving safety for patients. The product gained approval for market launch in China in late January and MicroPort is now applying for CE mark to bring this innovation to the European market.
Willis Intracranial Stent, another revolutionary device, is the first of its kind in China designed to treat intracranial aneurysms, and is expected to continue dominating the market in the next five years. MicroPort intends to launch Willis into the international markets in 2015.
"MicroPort is expanding toward a diversified global conglomeration from a new start," said Bo Peng, Chairman of Greater China Executive Committee and Chief Marketing Officer, referring to the company’s recent developments, such as its large outbound acquisitions of Wright OrthoRecon business in 2013, and the latest move to establish a joint venture with Italy-based Sorin Group for CRM business. "At this point, we are looking forward to seeing more distributors join us and to build an even more successful future together."
"We have built wealth by selling MicroPort’s products as a distributor in the past 10 years," said Xianghong Fang, General Manager of Beijing Kerui Huakang Medical Company. "We are expecting the next 10 years working with MicroPort to bring great success, with so many promising products newly released."